Cargando…

Integrins and p53 pathways in glioblastoma resistance to temozolomide

Glioblastoma is the most common malignant primary brain tumor. Surgical resection, postoperative radiotherapy plus concomitant and adjuvant chemotherapy with temozolomide (TMZ) is the standard of care for newly diagnosed glioblastoma. In the past decade, efforts have been made to decipher genomic an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin, Sophie, Janouskova, Hana, Dontenwill, Monique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2012
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484330/ https://www.ncbi.nlm.nih.gov/pubmed/23120745 http://dx.doi.org/10.3389/fonc.2012.00157

Ejemplares similares

Temozolomide-Acquired Resistance Is Associated with Modulation of the Integrin Repertoire in Glioblastoma, Impact of α5β1 Integrin
por: Sani, Saidu, et al.
Publicado: (2022)

Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma
por: Yoshimoto, Koji, et al.
Publicado: (2012)

An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
por: Teraiya, Milan, et al.
Publicado: (2023)

Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide
por: Llaguno-Munive, Monserrat, et al.
Publicado: (2020)

LAPTM5–CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance
por: Berberich, Anne, et al.
Publicado: (2020)

Corrigendum: Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide
por: Llaguno-Munive, Monserrat, et al.
Publicado: (2021)

BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53
por: Nie, Er, et al.
Publicado: (2016)

Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas
por: Chiang, Ming-Fu, et al.
Publicado: (2013)

Valproic Acid Enhanced Temozolomide-Induced Anticancer Activity in Human Glioma Through the p53–PUMA Apoptosis Pathway
por: Tsai, Hong-Chieh, et al.
Publicado: (2021)

Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomide
por: Bobola, Michael S., et al.
Publicado: (2012)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021)

Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of Glioblastomas
por: Cai, Hong-Qing, et al.
Publicado: (2020)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Molecular Evolution of a Glioblastoma Controlled With Tumor Treating Fields and Concomitant Temozolomide
por: Robins, H. Ian, et al.
Publicado: (2018)

Role of Integrins in Resistance to Therapies Targeting Growth Factor Receptors in Cancer
por: Cruz da Silva, Elisabete, et al.
Publicado: (2019)

Induction Of XLF And 53BP1 Expression Is Associated With Temozolomide Resistance In Glioblastoma Cells
por: Zhang, Tongxia, et al.
Publicado: (2019)

Hypoxia-Inducible Factor-1α Activity as a Switch for Glioblastoma Responsiveness to Temozolomide
por: Lo Dico, Alessia, et al.
Publicado: (2018)

Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme
por: Greer, Liana, et al.
Publicado: (2017)

One-Year Outcome of Multiple Blood–Brain Barrier Disruptions With Temozolomide for the Treatment of Glioblastoma
por: Park, So Hee, et al.
Publicado: (2020)

Revisiting the Immunological Aspects of Temozolomide Considering the Genetic Landscape and the Immune Microenvironment Composition of Glioblastoma
por: Di Ianni, Natalia, et al.
Publicado: (2021)

Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study
por: Chen, Jie, et al.
Publicado: (2022)

Glioblastoma Metabolism: Insights and Therapeutic Strategies
por: Bernhard, Chloé, et al.
Publicado: (2023)

β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer
por: Blandin, Anne-Florence, et al.
Publicado: (2015)

Downregulation of Leucine-Rich Repeat-Containing 8A Limits Proliferation and Increases Sensitivity of Glioblastoma to Temozolomide and Carmustine
por: Rubino, Sebastian, et al.
Publicado: (2018)

Cost-Effectiveness of [(18)F] Fluoroethyl-L-Tyrosine for Temozolomide Therapy Assessment in Patients With Glioblastoma
por: Baguet, Tristan, et al.
Publicado: (2019)

The Definition and Delineation of the Target Area of Radiotherapy Based on the Recurrence Pattern of Glioblastoma After Temozolomide Chemoradiotherapy
por: Zheng, Lin, et al.
Publicado: (2021)

Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma
por: She, Lei, et al.
Publicado: (2021)

A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma
por: Attarian, Fahimeh, et al.
Publicado: (2021)

Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts
por: Nishri, Yossi, et al.
Publicado: (2022)

The p53 Pathway in Glioblastoma
por: Zhang, Ying, et al.
Publicado: (2018)

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma
por: Fine, Howard, et al.
Publicado: (2023)

A Potential Mechanism of Temozolomide Resistance in Glioma–Ferroptosis
por: Hu, Zhifang, et al.
Publicado: (2020)

Anticancer Properties of the Antipsychotic Drug Chlorpromazine and Its Synergism With Temozolomide in Restraining Human Glioblastoma Proliferation In Vitro
por: Matteoni, Silvia, et al.
Publicado: (2021)

Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma
por: Miller, Ryan, et al.
Publicado: (2022)

Cyclooxygenase-2 Upregulated by Temozolomide in Glioblastoma Cells Is Shuttled In Extracellular Vesicles Modifying Recipient Cell Phenotype
por: Lombardi, Francesca, et al.
Publicado: (2022)

RNA Aptamers Targeting Integrin α5β1 as Probes for Cyto- and Histofluorescence in Glioblastoma
por: Fechter, Pierre, et al.
Publicado: (2019)

Expression Analysis of α5 Integrin Subunit Reveals Its Upregulation as a Negative Prognostic Biomarker for Glioblastoma
por: Etienne-Selloum, Nelly, et al.
Publicado: (2021)

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
por: JIAPAER, Shabierjiang, et al.
Publicado: (2018)

Integrin Beta 5 Is a Prognostic Biomarker and Potential Therapeutic Target in Glioblastoma
por: Zhang, Lu-yang, et al.
Publicado: (2019)

p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis
por: MIAO, WANG, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jt8t9h7eeaf12vh6rqfht3e737